Drug Overview: QVM149

  • ID: 4533479
  • Report
  • 15 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
QVM149: Asthma

List of Figures
Figure 55: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 56: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll